Funding · Healthcare & Life Sciences

Pandorum raises $18m Series B for exosome therapy

By Startup Enthusiast · 9 February 2026

What they do

Pandorum develops programmable regenerative medicine using tunable exosome-based therapies to reprogram damaged tissue

The company raised $18 million in a Series B round led by Protons Corporate to advance its lead drug Kuragenx

Funds will support clinical development of Kuragenx and scale global manufacturing with partners like AGC Biologics

Pandorum Technologies has closed an $18 million Series B funding round.
Protons Corporate led the investment in the biotech startup.
Participants included Galentic Pharma, Ashish Kacholia, Noblevast Advisory, Avinya Fund, and the Burman Family.
The company was founded in 2011 by co-founders Tuhin Bhowmick and Arun Chandru.
This is the latest capital raise for the Bengaluru-headquartered firm.
The transaction involved guidance from advisor Bandana Kankani.
The company operates in India and the United States.
Previous funding included an $11 million Series A extension secured last year.

The capital supports the clinical development of its lead program Kuragenx.
Pandorum aims to expand into markets in the US, Japan, and the Middle East.
The funding helps scale global manufacturing operations for its therapies.
The move aligns with government targets for a $300 billion bioeconomy by 2030.
Biotech ventures have grown significantly from approximately 50 to 11,000 over the past decade.

Pandorum specializes in programmable regenerative medicine and tunable exosome-based therapies.
Its platform integrates biology, engineering, and computational methods to reprogram pathological tissue states.
The goal is to restore functional recovery in conditions like inflammation and fibrosis.
The lead program is Kuragenx, an ophthalmology-focused exosome therapy.
Primary clinical focus includes ocular surface diseases such as Stevens–Johnson Syndrome and Neurotrophic Keratitis.
Kuragenx has received US FDA Orphan Drug Designation.
The company is expanding into inflammatory and degenerative conditions affecting lungs, liver, and the nervous system.
Historical work included creating 3D-printed human tissues for medical research.
Other products include bio-engineered corneal therapy and tissue models for drug testing.
Manufacturing partnerships include AGC Biologics in Italy and Nucelion Therapeutics in Asia-Pacific.

Pandorum plans to advance the clinical development of its lead drug Kuragenx.
The company intends to scale global manufacturing capabilities.
Expansion into the US, Japan, and the Middle East is planned.
The firm is exploring partnerships in the Middle East for regional access and distribution.

Protons Corporate (lead) — Led the Series B funding round for Pandorum Technologies.
Galentic Pharma (co-lead) — Participated in the Series B funding round.
Ashish Kacholia (participated) — Individual investor participating in the Series B round.
Noblevast Advisory (participated) — Advisory firm participating in the Series B funding.
Avinya Fund (participated) — Fund participating in the Series B investment.
Burman Family (participated) — Family office or group participating in the Series B round.

Product: based biotech startup
Customers: Hospitals and patients seeking regenerative therapies for corneal blindness and other tissue damage.
How it makes money: Developing and commercializing regenerative therapies, with revenue from treatment services and potential licensing deals.
What sets it apart: Proprietary platform combining biology, engineering, and computation to create tunable, programmable regenerative therapies.